Revista de Ciências Biomédicas e Farmacêuticas

A broad-spectrum of Posaconazole against Fungal Infections

Abstract

Tosin Adetobi*

Posaconazole is a pinch- generation triazole agent with a potent and broad antifungal in vitro exercise against a range of different Candida species, Aspergillus species, Cryptococcus neoformans, the zygomycetes, and other filamentous fungi. Rfungal pathogens, including Aspergillusspp. and Candida spp. It's structurally related to itraconazole and inhibits lanosterol 14α-demethylase (CYP51), blocking the compound of ergosterol behaving in disabled cell membrane stability and accumulation of precursors leading to fungistatic or fungicidal paraphernalia. Posaconazole (Noxafil, Schering Corporation, Kenilworth, NJ) was approved by the Food and Drug Administration for use as prophylaxis against invasive Aspergillus and Candida infections in immunocompromised case. Posaconazole differs in structure from the compact triazoles fluconazole and voriconazole in part by virtue of its extended side chain, a affection held in common with itraconazole.